Generic placeholder image

Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)

Editor-in-Chief

ISSN (Print): 1871-5222
ISSN (Online): 1875-6115

Effects of Statins on Transplant Graft Arterial Diseases

Author(s): Koichi Shimizu

Volume 8, Issue 2, 2008

Page: [141 - 150] Pages: 10

DOI: 10.2174/187152208784587872

Price: $65

Abstract

Despite the development of effective immunosuppressive therapy, transplant graft arterial disease (GAD) remains the major limitation to long-term graft survival. Multiple immune and nonimmune risk factors contribute to this vasculopathic disease process; the interplay between host inflammatory cells and donor endothelial cells results in an intimal hyperplastic lesion, whereas alloantigenindependent factors such as prolonged ischemia, surgical manipulation, ischemia-reperfusion injury, and hyperlipidemia may enhance antigen- dependent events, leading to ischemia and graft failure. Several studies suggest that the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, or statins, exert cholesterol-independent immunosuppressive effects beyond their original lipidlowering effects. Clinical studies demonstrate that statins reduce GAD in human cardiac allografts, improving chances for survival, although it remains unclear whether this is secondary to cholesterol-lowering or other mechanisms. Further studies will provide a firm rationale for using statins in organ transplantation.

Keywords: Graft arterial disease, immunosuppressive effects, major histocompatibility complex


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy